Texas Permanent School Fund Corp Has $3.63 Million Stock Position in Cencora, Inc. $COR

Texas Permanent School Fund Corp reduced its stake in Cencora, Inc. (NYSE:COR) by 37.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,118 shares of the company’s stock after selling 7,186 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Cencora were worth $3,634,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its position in shares of Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the period. Caldwell Trust Co acquired a new position in Cencora in the second quarter valued at about $46,000. Twin Peaks Wealth Advisors LLC acquired a new position in Cencora in the second quarter valued at about $52,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Cencora during the second quarter worth about $61,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several analyst reports. Robert W. Baird set a $392.00 target price on shares of Cencora in a research report on Tuesday. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. TD Cowen boosted their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday. Finally, UBS Group lifted their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $373.25.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $340.71 on Friday. The company has a market cap of $66.09 billion, a price-to-earnings ratio of 42.86, a PEG ratio of 1.63 and a beta of 0.63. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm has a 50 day simple moving average of $346.02 and a 200 day simple moving average of $312.67. Cencora, Inc. has a one year low of $223.92 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.